A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Latest Information Update: 05 Jan 2023
Price :
$35 *
At a glance
- Drugs Labuvirtide (Primary) ; Teropavimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Frontier Biotechnologies
- 28 Sep 2021 Planned primary completion date changed from 1 Jul 2022 to 1 Nov 2022.
- 28 Sep 2021 Planned initiation date (Estimated date of first participant enrolment) changed from 25 Dec 2020 to 30 Nov 2021.
- 23 Nov 2020 Planned initiation date (Estimated date of first participant enrollement) changed from 25 Oct 2020 to 25 Dec 2020.